Can also occur in rare circumstances when virally* Correspondence: lisa.l.
Can also occur in rare circumstances when virally* Correspondence: [email protected] Co-authors’ are Ivy H. Song, Niki Arya, Mike Choukour, Jian Zong, Shu-Pang Huang, Timothy Eley, Brian Wynne and Ann M. Buchanan. 1 ViiV Healthcare, Research Triangle Park, NC, USA Full list of author information is available at the end of the articleinfected bodily fluids come into contact with a noninfected PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/26780312 person’s bloodstream, mucous membranes, or damaged tissue such as through use of contaminated needles or other medical equipment, transfusion of virally contaminated blood or blood products, or various other routes [1, 2]. Coinfection with both HIV and HCV is not uncommon because of shared transmission modes. Globally, approximately 7 million people are thought to be coinfected with both HIV and HCV and, in the United States, about one-quarter to one-third of HIV-infected individuals are estimated to be coinfected with HCV [3]. Infection with HCV can result in long-?2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International VesatolimodMedChemExpress Vesatolimod License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Ross et al. BMC Infectious Diseases (2016) 16:Page 2 ofterm illness and death, and viral hepatitis progresses faster and causes more liver-related health problems among people living with HIV than among those without HIV infection. Although combination antiretroviral therapy has extended the life expectancy of people with HIV, liver disease has become the leading cause of non-AIDSrelated deaths in this population, and HIV-infected people coinfected with HCV are at increased risk for serious, lifethreatening complications [3?]. Treatment for HCV infection has made remarkable progress in the last several years, from treatments with relatively low cure rates that typically included pegylated interferon alfa in combination with ribavirin, to all-oral, direct-acting antiviral regimens that produce sustained viral responses with cure rates exceeding 90 for many patient populations [5]. Dolutegravir (DTG, Tivicay? ViiV Healthcare, Research Triangle Park, NC) is an HIV-1 integrase strand transfer inhibitor approved by the Food and Drug Administration and the European Medicines Agency for the treatment of HIV-1 infection in a broad patient population [6, 7]. Daclatasvir (DCV, DaklinzaTM, Bristol-Myers Squibb, Princeton, NJ) is an inhibitor of the HCV nonstructural protein NS5A and has been approved by the European Medicines Agency for use in combination with other medicinal products across genotypes 1, 3, and 4 for the treatment of chronic HCV infection in adults and by the Food and Drug Administration for the treatment PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28192408 of chronic HCV genotype 3 infection in adults [8, 9]. Because DTG and DCV may be concomitantly administered in subjects coinfected with HIV-1 and HCV, a drug interaction study between DTG and DCV was warranted to evaluate the pharmacokinetics (PK) of both drugs, as well as patient safety and drug tolerability when these drugs are coadministered.MethodsStudy design and sub.
